590 related articles for article (PubMed ID: 12186794)
1. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
Packer M; Califf RM; Konstam MA; Krum H; McMurray JJ; Rouleau JL; Swedberg K
Circulation; 2002 Aug; 106(8):920-6. PubMed ID: 12186794
[TBL] [Abstract][Full Text] [Related]
2. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA;
Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927
[TBL] [Abstract][Full Text] [Related]
3. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.
Rouleau JL; Pfeffer MA; Stewart DJ; Isaac D; Sestier F; Kerut EK; Porter CB; Proulx G; Qian C; Block AJ
Lancet; 2000 Aug; 356(9230):615-20. PubMed ID: 10968433
[TBL] [Abstract][Full Text] [Related]
4. Omapatrilat--the story of Overture and Octave.
Coats AJ
Int J Cardiol; 2002 Nov; 86(1):1-4. PubMed ID: 12243845
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
Kostova E; Jovanoska E; Zafirov D; Jakovski K; Maleska V; Slaninka-Miceska M
Bratisl Lek Listy; 2005; 106(12):407-11. PubMed ID: 16642666
[TBL] [Abstract][Full Text] [Related]
6. Recent clinical trials with omapatrilat: new developments.
Zanchi A; Maillard M; Burnier M
Curr Hypertens Rep; 2003 Aug; 5(4):346-52. PubMed ID: 12844471
[TBL] [Abstract][Full Text] [Related]
7. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats.
Pu Q; Touyz RM; Schiffrin EL
J Hypertens; 2002 May; 20(5):899-907. PubMed ID: 12011651
[TBL] [Abstract][Full Text] [Related]
8. [Omapatrilat for treatment of heart failure].
Yamazaki T
Nihon Rinsho; 2007 May; 65 Suppl 5():173-5. PubMed ID: 17571381
[No Abstract] [Full Text] [Related]
9. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats.
Pu Q; Amiri F; Gannon P; Schiffrin EL
J Hypertens; 2005 Feb; 23(2):401-9. PubMed ID: 15662229
[TBL] [Abstract][Full Text] [Related]
10. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study.
Mitchell GF; Izzo JL; Lacourcière Y; Ouellet JP; Neutel J; Qian C; Kerwin LJ; Block AJ; Pfeffer MA
Circulation; 2002 Jun; 105(25):2955-61. PubMed ID: 12081987
[TBL] [Abstract][Full Text] [Related]
11. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.
Kostis JB; Packer M; Black HR; Schmieder R; Henry D; Levy E
Am J Hypertens; 2004 Feb; 17(2):103-11. PubMed ID: 14751650
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-neprilysin inhibition versus enalapril in heart failure.
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile MR;
N Engl J Med; 2014 Sep; 371(11):993-1004. PubMed ID: 25176015
[TBL] [Abstract][Full Text] [Related]
13. Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure.
Eisenstein EL; Nelson CL; Simon TA; Smitten AL; Lapuerta P; Mark DB
Am Heart J; 2002 Jun; 143(6):1112-7. PubMed ID: 12075271
[TBL] [Abstract][Full Text] [Related]
14. Combined neutral endopeptidase inhibitors.
Cuculi F; Erne P
Expert Opin Investig Drugs; 2011 Apr; 20(4):457-63. PubMed ID: 21323474
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure.
Sheth T; Parker T; Block A; Hall C; Adam A; Pfeffer MA; Stewart DJ; Qian C; Rouleau JL;
Am J Cardiol; 2002 Sep; 90(5):496-500. PubMed ID: 12208409
[TBL] [Abstract][Full Text] [Related]
16. Antianginal efficacy of omapatrilat in patients with chronic angina pectoris.
Chaitman BR; Ivleva AY; Ujda M; Lenis JH; Toth C; Stieber DM; Reisin LH; Pangerl AM; Friedman JB; Lawrence JH
Am J Cardiol; 2005 Jun; 95(11):1283-9. PubMed ID: 15904630
[TBL] [Abstract][Full Text] [Related]
17. Omapatrilat.
Armstrong PW; Lorell BH; Nissen S; Borer J
Circulation; 2002 Aug; 106(6):e9011-2. PubMed ID: 12187916
[No Abstract] [Full Text] [Related]
18. Vasopeptidase inhibitors in heart failure.
Dawson A; Struthers AD
J Renin Angiotensin Aldosterone Syst; 2002 Sep; 3(3):156-9. PubMed ID: 12563565
[TBL] [Abstract][Full Text] [Related]
19. Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects.
McClean DR; Ikram H; Mehta S; Heywood JT; Rousseau MF; Niederman AL; Sequeira RF; Fleck E; Singh SN; Coutu B; Hanrath P; Komajda M; Bryson CC; Qian C; Hanyok JJ;
J Am Coll Cardiol; 2002 Jun; 39(12):2034-41. PubMed ID: 12084605
[TBL] [Abstract][Full Text] [Related]
20. Omapatrilat. Bristol-Myers Squibb.
Tabrizchi R
Curr Opin Investig Drugs; 2001 Oct; 2(10):1414-22. PubMed ID: 11890357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
